- Home
- PBYI vs SANG Comparison
PBYI vs SANG Comparison
Compare PBYI & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SANG
- Stock Information
- Founded
- PBYI 2010
- SANG 1984
- Country
- PBYI United States
- SANG Canada
- Employees
- PBYI N/A
- SANG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SANG Computer Software: Programming Data Processing
- Sector
- PBYI Health Care
- SANG Technology
- Exchange
- PBYI Nasdaq
- SANG Nasdaq
- Market Cap
- PBYI 171.7M
- SANG 194.3M
- IPO Year
- PBYI N/A
- SANG 2021
- Fundamental
- Price
- PBYI $4.34
- SANG $6.16
- Analyst Decision
- PBYI Strong Buy
- SANG
- Analyst Count
- PBYI 1
- SANG 0
- Target Price
- PBYI $7.00
- SANG N/A
- AVG Volume (30 Days)
- PBYI 543.3K
- SANG 7.7K
- Earning Date
- PBYI 11-06-2025
- SANG 09-17-2025
- Dividend Yield
- PBYI N/A
- SANG N/A
- EPS Growth
- PBYI 434.29
- SANG N/A
- EPS
- PBYI 0.97
- SANG N/A
- Revenue
- PBYI $238,062,000.00
- SANG $238,264,000.00
- Revenue This Year
- PBYI N/A
- SANG N/A
- Revenue Next Year
- PBYI N/A
- SANG $2.38
- P/E Ratio
- PBYI $4.51
- SANG N/A
- Revenue Growth
- PBYI 8.63
- SANG N/A
- 52 Week Low
- PBYI $2.32
- SANG $4.08
- 52 Week High
- PBYI $6.07
- SANG $7.99
- Technical
- Relative Strength Index (RSI)
- PBYI 42.81
- SANG 61.00
- Support Level
- PBYI $4.49
- SANG $5.42
- Resistance Level
- PBYI $4.72
- SANG $6.46
- Average True Range (ATR)
- PBYI 0.26
- SANG 0.23
- MACD
- PBYI -0.12
- SANG 0.04
- Stochastic Oscillator
- PBYI 3.51
- SANG 70.67
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.